Rubella symptoms
- Children usually develop few or no symptoms, but adults may experience a 1–5-day prodrome of low-grade fever, headache, malaise, mild coryza, and conjunctivitis.
- 50%–80% of infected persons develop a maculopapular rash (fainter than a measles rash) that starts on the face and progresses from head to feet, becomes generalized in 24 hours and lasts a median of 3 days.
- Postauricular, occipital and posterior cervical lymphadenopathy is characteristic and precedes the rash by 5–10 days.
- Arthralgia or arthritis may occur in up to 70% of adult women; rarely in children or males.
- Rare complications include thrombocytopenic purpura and encephalitis.

Mode of transmission
Rubella is transmitted by inhalation of respiratory aerosols emitted when an infected person sneezes, coughs or talks. Rubella may also be spread by direct contact with respiratory secretions of infected persons.

Incubation period
The average incubation period is 17 days (range: 12–23 days).

Period of communicability
The infectious period for postnatal rubella is considered to be from 7 days before onset of rash to 7 days after onset of rash (day of rash onset is day 0).

Infants with congenital rubella syndrome (CRS) are presumed infectious at least through the first year of life unless 2 cultures of clinical specimens obtained 1 month apart after 3 months of age are negative for rubella virus.

Laboratory testing
Clinical diagnosis of rubella is unreliable, therefore, cases must be laboratory confirmed.

Detection of virus by real-time polymerase chain reaction (RT-PCR) at VRDL
- Rubella virus can be detected from nasal or throat swabs.
- Virus may be detected from 1 week before to 2 weeks after rash onset. However, maximum viral shedding occurs up to day 4 after rash onset.
- A urine specimen should also be collected for measles virus detection since testing for rubella and measles is often done concurrently.

Detection of IgM antibody
- Enzyme immunoassay (EIA) is the preferred testing method for IgM, using the capture technique.
- Rubella-specific IgM can usually be detected 4–30 days after onset of illness, and often for longer. Sera should be collected as early as possible after onset of illness. However, IgM antibodies may not be detectable before day 5 after rash onset. In case of a rubella IgM-negative result in specimens taken before day 5, serologic testing should be repeated on a specimen collected after day 5.
- Because rubella incidence is low, a high proportion of IgM-positive tests will likely be false positive. False positive serum rubella IgM tests may occur due to the presence of rheumatoid factors (indicating rheumatologic disease) or cross-reacting IgM, or infection with other viruses.

Detection of IgG antibody
- To detect a significant rise in rubella-specific IgG concentration, the first serum should be obtained as soon as possible after onset of illness and the second serum sample should be collected about 7–21 days after the first specimen.
- Tests for IgG antibody should be conducted on both acute-and convalescent-phase specimens at the same time with the same test to detect a four-fold rise in IgG titer.
CDC case classification

**Confirmed**
A case with or without symptoms who has laboratory evidence of rubella infection confirmed by one or more of the following laboratory tests:
- Isolation of rubella virus; or
- Detection of rubella-virus specific nucleic acid by polymerase chain reaction; or
- IgG seroconversion† or a significant rise between acute- and convalescent-phase titers in serum rubella IgG antibody level by any standard serologic assay; or
- Positive serologic test for rubella IgM antibody.*†

**OR**
An illness characterized by all of the following:
- Acute onset of generalized maculopapular rash; and
- Temperature greater than 99.0°F or 37.2°C; and
- Arthralgia, arthritis, lymphadenopathy, or conjunctivitis; and
- Epidemiologic linkage to a laboratory-confirmed case of rubella.

*Not explained by MMR vaccination in the previous 6-45 days.
†Not otherwise ruled out by more specific testing in a public health laboratory.

**Probable**
In the absence of a more likely diagnosis, an illness characterized by **all** of the following:
- Acute onset of generalized maculopapular rash; and
- Temperature greater than 99.0° F or 37.2° C, if measured; and
- Arthralgia, arthritis, lymphadenopathy, or conjunctivitis; and
- Lack of epidemiologic linkage to a laboratory-confirmed case of rubella; and
- Noncontributory or no serologic or virologic testing.

**Suspected**
Any generalized rash illness of acute onset that does not meet the criteria for probable or confirmed rubella or any other illness.

Definition of exposure
Non-transient (i.e., more than a few minutes) contact <6 feet of an infectious case, including any direct contact with case.

Postexposure prophylaxis
There is NO postexposure prophylaxis for persons exposed to a person who is infectious for rubella.

Neither rubella vaccine nor immune globulin (IG) is effective for postexposure prophylaxis for susceptible persons.

Postexposure vaccination of susceptible persons is recommended unless otherwise contraindicated, because if the current exposure to rubella does not cause infection, postexposure vaccination should induce protection against subsequent infection.

Recommended treatment
Treatment of rubella is supportive.

Definition of immunity
- Documentation of vaccination with at least one dose of MMR or other live rubella-containing vaccine administered on or after the first birthday;
- Serologic evidence of immunity‡ (rubella IgG positive);
- History of laboratory-confirmed rubella disease;
- Birth before 1957.§

*Persons who have an “equivocal” IgG test result and no documented doses of MMR vaccine should be considered rubella-susceptible.
‡Rubella IgG levels can wane over time resulting in falsely negative rubella IgG test results. Evidence suggests that persons with at least 1 documented dose of MMR are likely protected against rubella infection regardless of serologic testing results.
§Birth before 1957 provides only presumptive evidence of rubella immunity and does not guarantee that a person is immune to rubella. In premenopausal women who can become pregnant, only a positive serologic test for rubella antibody or documentation of appropriate vaccination should be accepted as evidence of immunity. Healthcare personnel born before 1957 also should not be presumed to be immune. Healthcare facilities should consider recommending at least one dose of MMR vaccine to unvaccinated healthcare personnel born before 1957 who do not have laboratory evidence of rubella immunity.
**Case investigation**

1. Assess the suspected case:
   - Confirm clinical signs and symptoms (at a minimum: rash, fever, arthralgia/arthritis, conjunctivitis, or lymphadenopathy).
   - Verify that suspected case could be susceptible to rubella (vaccination history).
   - Determine history of international travel or contact with international visitors ≤23 days of rash onset.
   - Determine if suspected case had contact with a person known to be infected with rubella, CRS, or a person with a rash illness.

2. Ensure that case is isolated immediately through day 7 after rash onset or until rubella is ruled out.

3. Report case to CDPH.

4. In consultation with CDPH, collect appropriate specimens and arrange for laboratory testing of suspected case at a public health laboratory.

5. If a pregnant woman is infected with rubella, immediate medical consultation is necessary.

6. Ensure that appropriate infection control precautions are taken to prevent additional exposures in healthcare settings.

7. Identify contacts and determine their immune status (refer to definitions of immunity in next section):
   - Identify all household contacts and determine their immune status to rubella.
   - Identify all other potentially exposed contacts from settings where neither the case nor contact were masked and determine their immune status to rubella.
   - Determine whether case was on a flight while infectious; collect flight information.

8. Refer exposed susceptible pregnant women to their prenatal care provider for consultation. Ensure that prenatal care providers receive rubella infection control guidance before an exposed pregnant woman presents for care.

9. Refer susceptible contacts for vaccination. Post-exposure vaccination will not prevent or alter the clinical severity of rubella infection. However, if the current exposure to rubella does not cause infection, vaccination should induce protection against infection from subsequent exposures.

10. Local health departments should recommend that rubella cases and susceptible contacts have no contact with pregnant women and persons without adequate proof of rubella immunity for 7 days after rash onset (cases) or from 7 days after the first exposure to 23 days after the last exposure to rubella (contacts).

**Exposed pregnant women**

The primary goals of rubella case investigations are to prevent the exposure of susceptible pregnant women to rubella (and thereby prevent cases of CRS), to assess the immune status of exposed pregnant women, and to identify rubella infections, particularly infections in pregnant women.

Every effort should be made to identify all pregnant women who might have been exposed to a case and evaluate these contacts serologically for rubella-specific IgG antibodies if their immune status is not known, i.e., no prior serologic testing for rubella during prenatal or healthcare worker screening.

All women of childbearing age who are contacts of a person with a suspected or confirmed case of rubella should have their pregnancy status determined.

If an unvaccinated pregnant woman is IgG negative, precautions should be taken to prevent any type of exposure to persons infected with rubella; these precautions may include ensuring rubella immunity of household contacts, restricting such pregnant women from settings where rubella infection has been identified, and advising against travel to areas where rubella is circulating.

**Rubella infection during pregnancy and congenital rubella syndrome**

When rubella infection occurs during pregnancy, especially during the first trimester, serious consequences can result. These include miscarriages, fetal deaths/stillbirths, and a constellation of severe birth defects known as congenital rubella syndrome (CRS). The most common congenital defects are cataracts, heart defects and hearing impairment.
Exposures in healthcare settings
- Exposed healthcare personnel without adequate evidence of immunity should be excluded from duty beginning 7 days after first exposure to rubella through either 23 days after last exposure or 7 days after rash appears.
- Exposed healthcare personnel who are vaccinated as part of control measures for a rubella exposure should be excluded from direct patient care for 23 days after the last exposure to rubella because effectiveness of postexposure vaccination in preventing rubella infection has not been shown.
- Because birth before 1957 does not guarantee rubella immunity, if an exposure occurs in a healthcare setting, healthcare facilities should recommend one dose of MMR vaccine for unvaccinated personnel born before 1957 who lack laboratory evidence of rubella immunity or laboratory confirmation of infection or disease.
- Exposed susceptible patients should be discharged <7 days after first exposure, if possible. If they cannot be discharged, they should be isolated in Droplet Precautions for 23 days after last exposure to rubella.

Exposures in schools or childcare centers
- In schools and childcare settings, exclusion of persons without acceptable evidence of rubella immunity may limit disease transmission and may help to rapidly raise the vaccination level in the target population.
- All persons who have been exempted from rubella vaccination for medical reasons or personal beliefs should also be excluded from attendance.
- Exclusion should continue until 23 days after the onset of rash of the last reported case-patient in the outbreak setting.
- Unvaccinated persons who receive MMR vaccine as part of the outbreak control may be immediately readmitted to school provided all persons without documentation of immunity have been excluded.

For more information
Contact the CDPH Immunization Branch at: 510-620-3737.